The MAP Kinase ERK2 Inhibits the Cyclic AMP-specific Phosphodiesterase HSPDE4D3 by Phosphorylating It at Ser579

Overview

Journal EMBO J

Specialties Biotechnology
Molecular Biology

Date 1999 Feb 18

PMID 10022832

Citations 80

Authors

R Hoffmann

G S Baillie

S J MacKenzie

S J Yarwood

M D Houslay

Affiliations

Soon will be listed here.

Abstract

The extracellular receptor stimulated kinase ERK2 (p42(MAPK))-phosphorylated human cAMP-specific phosphodiesterase PDE4D3 at Ser579 and profoundly reduced ( approximately 75%) its activity. These effects could be reversed by the action of protein phosphatase PP1. The inhibitory state of PDE4D3, engendered by ERK2 phosphorylation, was mimicked by the Ser579-->Asp mutant form of PDE4D3. In COS1 cells transfected to express PDE4D3, challenge with epidermal growth factor (EGF) caused the phosphorylation and inhibition of PDE4D3. This effect was blocked by the MEK inhibitor PD98059 and was not apparent using the Ser579-->Ala mutant form of PDE4D3. Challenge of HEK293 and F442A cells with EGF led to the PD98059-ablatable inhibition of endogenous PDE4D3 and PDE4D5 activities. EGF challenge of COS1 cells transfected to express PDE4D3 increased cAMP levels through a process ablated by PD98059. The activity of the Ser579-->Asp mutant form of PDE4D3 was increased by PKA phosphorylation. The transient form of the EGF-induced inhibition of PDE4D3 is thus suggested to be due to feedback regulation by PKA causing the ablation of the ERK2-induced inhibition of PDE4D3. We identify a novel means of cross-talk between the cAMP and ERK signalling pathways whereby cell stimuli that lead to ERK2 activation may modulate cAMP signalling.

Citing Articles

Nanodomain cAMP signaling in cardiac pathophysiology: potential for developing targeted therapeutic interventions.

Zaccolo M, Kovanich D Physiol Rev. 2024; 105(2):541-591.

PMID: 39115424 PMC: 7617275. DOI: 10.1152/physrev.00013.2024.

Phosphodiesterase 4D activity in acrodysostosis-associated neural pathology: too much or too little?.

Gardner O, Bai T, Baillie G, Ferretti P Brain Commun. 2024; 6(4):fcae225.

PMID: 38983619 PMC: 11232698. DOI: 10.1093/braincomms/fcae225.

Abnormal phosphorylation / dephosphorylation and Ca dysfunction in heart failure.

Liu Y, Wang Q, Song Y, Song X, Fan Y, Kong L Heart Fail Rev. 2024; 29(4):751-768.

PMID: 38498262 DOI: 10.1007/s10741-024-10395-w.

Phosphodiesterase-4 Inhibition in Parkinson's Disease: Molecular Insights and Therapeutic Potential.

Roy D, Balasubramanian S, Krishnamurthy P, Sola P, Rymbai E Cell Mol Neurobiol. 2023; 43(6):2713-2741.

PMID: 37074485 PMC: 11410141. DOI: 10.1007/s10571-023-01349-1.

Immune Checkpoint Inhibitors and RAS-ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma.

Morante M, Pandiella A, Crespo P, Herrero A Biomolecules. 2022; 12(11).

PMID: 36358912 PMC: 9687808. DOI: 10.3390/biom12111562.

References

Torphy T, Undem B, Cieslinski L, Luttmann M, Reeves M, Hay D . Identification, characterization and functional role of phosphodiesterase isozymes in human airway smooth muscle. J Pharmacol Exp Ther. 1993; 265(3):1213-23. View

Torphy T . Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med. 1998; 157(2):351-70. DOI: 10.1164/ajrccm.157.2.9708012. View

Houslay M, Sullivan M, Bolger G . The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. Adv Pharmacol. 1998; 44:225-342. DOI: 10.1016/s1054-3589(08)60128-3. View

Hoffmann R, Wilkinson I, McCallum J, Engels P, Houslay M . cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model. Biochem J. 1998; 333 ( Pt 1):139-49. PMC: 1219566. DOI: 10.1042/bj3330139. View

Shakur Y, Pryde J, Houslay M . Engineered deletion of the unique N-terminal domain of the cyclic AMP-specific phosphodiesterase RD1 prevents plasma membrane association and the attainment of enhanced thermostability without altering its sensitivity to inhibition by rolipram. Biochem J. 1993; 292 ( Pt 3):677-86. PMC: 1134167. DOI: 10.1042/bj2920677. View

Bolger G, Michaeli T, Martins T, John T, Steiner B, Rodgers L . A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs. Mol Cell Biol. 1993; 13(10):6558-71. PMC: 364715. DOI: 10.1128/mcb.13.10.6558-6571.1993. View

Wu J, Dent P, Jelinek T, Wolfman A, Weber M, Sturgill T . Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3',5'-monophosphate. Science. 1993; 262(5136):1065-9. DOI: 10.1126/science.7694366. View

Cook S, McCormick F . Inhibition by cAMP of Ras-dependent activation of Raf. Science. 1993; 262(5136):1069-72. DOI: 10.1126/science.7694367. View

Cook S, Rubinfeld B, Albert I, McCormick F . RapV12 antagonizes Ras-dependent activation of ERK1 and ERK2 by LPA and EGF in Rat-1 fibroblasts. EMBO J. 1993; 12(9):3475-85. PMC: 413624. DOI: 10.1002/j.1460-2075.1993.tb06022.x. View

10.

Hordijk P, Verlaan I, Jalink K, van Corven E, Moolenaar W . cAMP abrogates the p21ras-mitogen-activated protein kinase pathway in fibroblasts. J Biol Chem. 1994; 269(5):3534-8. View

11.

Sette C, Iona S, Conti M . The short-term activation of a rolipram-sensitive, cAMP-specific phosphodiesterase by thyroid-stimulating hormone in thyroid FRTL-5 cells is mediated by a cAMP-dependent phosphorylation. J Biol Chem. 1994; 269(12):9245-52. View

12.

Scott J, McCartney S . Localization of A-kinase through anchoring proteins. Mol Endocrinol. 1994; 8(1):5-11. DOI: 10.1210/mend.8.1.8152430. View

13.

Blumer K, Johnson G . Diversity in function and regulation of MAP kinase pathways. Trends Biochem Sci. 1994; 19(6):236-40. DOI: 10.1016/0968-0004(94)90147-3. View

14.

Beavo J, Conti M, Heaslip R . Multiple cyclic nucleotide phosphodiesterases. Mol Pharmacol. 1994; 46(3):399-405. View

15.

LOBBAN M, Shakur Y, Beattie J, Houslay M . Identification of two splice variant forms of type-IVB cyclic AMP phosphodiesterase, DPD (rPDE-IVB1) and PDE-4 (rPDE-IVB2) in brain: selective localization in membrane and cytosolic compartments and differential expression in various brain regions. Biochem J. 1994; 304 ( Pt 2):399-406. PMC: 1137507. DOI: 10.1042/bj3040399. View

16.

Rubin C . A kinase anchor proteins and the intracellular targeting of signals carried by cyclic AMP. Biochim Biophys Acta. 1994; 1224(3):467-79. View

17.

Shakur Y, Wilson M, Pooley L, LOBBAN M, Griffiths S, Campbell A . Identification and characterization of the type-IVA cyclic AMP-specific phosphodiesterase RD1 as a membrane-bound protein expressed in cerebellum. Biochem J. 1995; 306 ( Pt 3):801-9. PMC: 1136592. DOI: 10.1042/bj3060801. View

18.

Bolger G . Molecular biology of the cyclic AMP-specific cyclic nucleotide phosphodiesterases: a diverse family of regulatory enzymes. Cell Signal. 1994; 6(8):851-9. DOI: 10.1016/0898-6568(94)90018-3. View

19.

Scotland G, Houslay M . Chimeric constructs show that the unique N-terminal domain of the cyclic AMP phosphodiesterase RD1 (RNPDE4A1A; rPDE-IVA1) can confer membrane association upon the normally cytosolic protein chloramphenicol acetyltransferase. Biochem J. 1995; 308 ( Pt 2):673-81. PMC: 1136979. DOI: 10.1042/bj3080673. View

20.

Pang L, Sawada T, Decker S, Saltiel A . Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by nerve growth factor. J Biol Chem. 1995; 270(23):13585-8. DOI: 10.1074/jbc.270.23.13585. View